Quality of Life
Conditions
Brief summary
Despite its beneficial effect, ureteral stents may produce symptoms (such as hematuria, dysuria, frequency, urgency, urge incontinence and suprapubic or flank pain) that affect the quality of life in 70-80%. This study will be conducted to evaluate the role of Phosphodiestrase 5 inhibitor (Sildenafil Citrate) in relieving these symptoms.
Detailed description
Adult patient (\>18 years) who will undergo ureteral stent fixation after endoscopic procedures will be randomized between the study arms. Exclusion criteria: 1. Patients who had lower urinary tract symptoms before stent fixation. 2. Ureteral stent fixation after open surgery. 3. Known contraindications to Sildenafil Citrate
Interventions
DRUGSildenafil
DRUGPlacebo
Sponsors
Mansoura University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1\. Patient aged \>18 years
Exclusion criteria
1. Patients who had LUTS before DJ stent fixation 2. DJ stent fixation after open surgery 3. Contraindication to Sildenafil citrate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ureteral Stent Symptoms Questionnaire (USSQ) Score | 2-4 weeks | Comparison of total USSQ scores between study arms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events | 2-4 weeks | Analyzing frequency and severity of side effects of Sildenafil |
Countries
Egypt
Outcome results
None listed